E Fund Management Co., Ltd. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
E Fund Management Co., Ltd. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$335
-16.5%
9,404
+8.2%
0.02%
-21.9%
Q2 2023$401
+0.2%
8,693
-12.8%
0.03%
+10.3%
Q1 2023$400
-17.0%
9,964
-4.2%
0.03%
-27.5%
Q4 2022$482
-99.9%
10,398
+7.5%
0.04%
+8.1%
Q3 2022$401,000
-23.5%
9,673
+10.2%
0.04%
-21.3%
Q2 2022$524,000
+75.8%
8,779
+114.1%
0.05%
+370.0%
Q1 2022$298,0004,1010.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders